Following AbbVie's pending acquisition of Apogee Therapeutics, big pharma is actively seeking clinical-stage biotech firms with late-stage data and strategic fit in immunology, obesity, or oncology. Among Nasdaq-listed biotechs, Syndax Pharmaceuticals stands out as the most likely acquisition target due to its smaller market cap, commercial-stage products, strong revenue growth, and a strategic partner already involved. Viking Therapeutics and Nektar Therapeutics also attract attention but have larger market caps and more cash, reducing acquisition urgency. The Apogee deal sets a precedent for premium valuations in this space, making Syndax the top candidate for a takeover in the near term.
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
Canada has approved Boey®, the first rapid-onset and short-duration botulinum neurotoxin serotype E, for temporarily improving moderate to severe glabellar (frown) lines. Developed by Allergan Aesthetics, Boey® offers results visible as early as eigh...
The European Union has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C virus (HCV) infection in adults and children aged 3 and older. This is the only treatment in the EU approved for both acute and chronic HCV, enabling ea...
The European Commission has approved SKYRIZI (risankizumab) for treating moderate to severe plaque psoriasis in children and adolescents aged six and older. This approval includes a new 55 mg pre-filled syringe designed for weight-based dosing in pat...
AbbVie announced it will acquire Apogee Therapeutics in a $10.9 billion all-cash deal, gaining clinical-stage therapies for inflammatory and immunological diseases like atopic dermatitis and asthma. The acquisition includes Apogee's lead drug zumilok...
